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Abstract 
The objective of the present study was to investigate the applicability of matrix 
type mucoadhesive oral multiple unit systems (MUS) for sustaining the release 
of ornidazole in the gastrointestinal tract (GIT).The MUS were prepared by 
ionotropic gelation method using chitosan and hydroxypropyl methyl cellulose 
K4M (HPMC K4M) according to 3
2 factorial designs and were evaluated in vitro 
and in vivo. The particle size length ranged from 0.78 to 1.30 mm and breadth 
from 0.76 to 1.30 mm, respectively. The entrapment efficiency was in range of 
80 to 96%. The rapid wash-off test was observed faster at intestinal pH 6.8 as 
compared to acidic pH 1.2. The fluoroscopic study revealed the retention of 
MUS in GIT for more than 5 hours. The pharmacokinetic parameters Cmax, Tmax, 
mean residence time (MRT) and area under curve (AUC) of developed MUS 
were found to be improved significantly (p<0.05) when compared with marketed 
immediate release tablets each containing 500 mg of drug. This study 
demonstrates that the MUS could be a good alternative to immediate release 
tablets to deliver ornidazole and expected to be less irritant to gastric and 
intestinal mucosa.  
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Introduction 
Oral administration of drugs by means of controlled release delivery systems should 
ideally enable to obtain the required plasma levels and to keep them steady for a 
prolonged period of time. Unfortunately, this ideal therapeutic target cannot systemically 
be achieved [1]; in spite of the progresses accomplished today in formulation and control 
of drug release kinetics from such type of dosage forms. The main limitations come from 
the variability of gastrointestinal transit time and from the non-uniformity of drug absorption 
throughout the gastrointestinal tract (GIT) [2]. These physiological limitations could be 
overcome by prolonging the gastric residence time of the dosage forms. Therefore, it 
would be beneficial to develop a sustained release formulation which remains at the 
absorption site for an extended period of time. Several approaches have been immersed 
to prolong the gastric residence time of the dosage forms at the absorption site and one of 
these is the development of oral controlled release bioadhesive system [3, 4]. The purpose 
of designing MUS dosage form is to develop a reliable formulation that has all the 
advantages of a single unit formulations and yet devoid of the danger of alteration in drug 
release profile and formulation behaviour due to unit to unit variation, change in gastro-
luminal pH and enzyme population. A generally accepted view is that MUS perform better 
in vivo than single unit systems, as they spread out throughout the length of the intestine 
causing less irritation, enjoy a slower transit through the GIT and give a more reproducible 
drug release [5]. MUS, in general, have the potential to be used for targeted and controlled 
release drug delivery; but coupling of bioadhesive properties to MUS has additional 
advantages, e.g. efficient absorption and enhanced bioavailability of the drugs due to a 
high surface to volume ratio, a much more intimate contact with the mucus layer and 
specific targeting of drugs to the absorption site [6]. 
 Ornidazole, a water-soluble drug is widely used as an anti-amoebic and antiprotozoal as 
well as to prevent recurrence of peptic ulcer disease caused by H. Pylori. Ornidazole has 
better oral bioavailability more than 90%, gets absorbed from small intestine with MIC of 
0.25 mg/l [7]. The adverse effects of ornidazole are urticaria, pruritus, flushing, dry mouth, 
feeling of pelvic pressure, vertigo, headache, ataxia and insomnia which involve the GIT 
and nervous system, especially with high doses. Reduction of side effects while prolonging 
its action by using controlled release of oral dosage forms is highly desirable for such 
category of drugs [8, 9].  
Chitosan, the n-acetylated product of the polysaccharide chitin, is gaining increasing 
importance in drug delivery to the GIT and also enhances the penetration of 
macromolecules across the intestinal and nasal barriers [10]. Sodium alginate, an anionic 
polysaccharide forms a cured gel matrix in the presence of calcium. Calcium alginate is 
able to incorporate drug within its gel matrix, and thus acts as a vehicle for the sustained 
release of orally administered drugs [11]. Chitosan and sodium alginate were selected 
owing to their good biocompatibility, non-toxicity and biodegradability. Statistical 
optimization designs have been previously documented for the formulation of many 
pharmaceutical oral solid dosage forms. Additionally, it is a powerful, efficient and 
systematic tool that shortens the time required for the development of pharmaceutical 
dosage forms [12]. 
Side effects, mainly at the gastric level, are well known, following oral administration of an 
ornidazole drug. Therefore, the efforts of many researchers have been concerned to solve   Optimization, Characterisation and Pharmacokinetic Studies of Mucoadhesive Oral Multiple Unit …  183 
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these problems through a variety of techniques of protection of the gastric mucosa or 
alternatively to prevent the ornidazole release in this district. The objective of the present 
study was to evaluate the potential utility of natural biopolymers such as chitosan in 
combination with HPMC in sustaining the release of ornidazole in GIT. We also 
investigated the possible applicability of chitosan treated matrix type systems as sustained 
release system. We prepared MUS of dispersed chitosan and HPMC using aqueous 
solvents and evaluated in vitro and in vivo. 
Results and Discussion 
MUS of ornidazole consisting of chitosan and HPMC K4M in varying compositions could 
be prepared by the orifice-ionic gelation process by 3
2 factorial designs. The data analysis 
of parameters obtained from various batches for particle size distribution, drug entrapment 
efficiency and drug release were subjected to multiple regression analysis. Positive sign of 
the term indicates positive (additive) effect, while negative sign indicates negative 
(antagonistic) effect of the factor on the response. This design was selected as it provides 
sufficient degrees of freedom to resolve the main effects as well as the factor interactions. 
The data analysis was done by using “PCP Disso V3” software (IIPC, PCP, Pune, India) 
and fitted in equation: 
Eq. 1.   Y = β0 + β1 Χ1 + β2 Χ2 + β11Χ1
2 + β22Χ
2
2 + β12Χ1Χ2 
Where, Y represents measured response; X levels of factors, and β, coefficient computed 
from the responses of the formulations. 
Tab. 1.   3
2 Factorial design: composition and characteristics of ORZ-loaded MUS. 
Particle size (mm) 
Formul. 
Chitosan 
Amount (mg) 
(X1)/code 
HPMC K4M 
Amount (mg)
(X2)/code 
Length  
Mean ± (SD)
Breadth  
Mean ± (SD) 
Entrapment 
Efficiency (%)
Mean ± (SD) 
ORZ-1  1.00 (–1)  1.00 (–1)  0.78 ± 0.25  0.76 ± 0.45  88 ± 0.56 
ORZ-2  1.00 (–1)  1.50   (0)  0.80 ± 0.14  0.80 ± 0.48  84 ± 0.50 
ORZ-3  1.00 (–1)  2.00 (+1)  1.03 ± 0.23  1.01 ± 0.84  80 ± 0.45 
ORZ-4  1.75   (0)  1.00 (–1)  0.87 ± 0.32  0.85 ± 0.23  92 ± 0.45 
ORZ-5  1.75   (0)  1.50   (0)  0.89 ± 0.12  0.88 ± 0.36  96 ± 0.20 
ORZ-6  1.75   (0)  2.00 (+1)  1.13 ± 0.22  1.13 ± 0.28  95 ± 0.20 
ORZ-7  2.50 (+1)  1.00 (–1)  0.93 ± 0.21  0.94 ± 0.23  91 ± 0.20 
ORZ-8  2.50 (+1)  1.50   (0)  1.22 ± 0.37  1.23 ± 0.23  90 ± 0.40 
ORZ-9  2.50 (+1)  2.00 (+1)  1.30 ± 0.21  1.30 ± 0.21  84 ± 0.55 
SD indicates standard deviation. Independent variables level: low (–1), medium (0), high (+1), HPMC-
Hydroxypropyl methyl cellulose. 
 
Determination of particle size 
The results of evaluation of the micromeritic properties are shown in Table 1. The length 
and the breadth of MUS ranged from 0.78 ± 0.25 to 1.30 ± 0.21 mm and 0.76 ± 0.45 to 
1.30 ± 0.21 mm, respectively. The MUS of ORZ-4, ORZ-5 and ORZ-6 were found to be 184  G. S. Asane et al.:  
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discrete, spherical, free-flowing and of the mono-lithic matrix type. The batches of ORZ-7, 
ORZ-8 and ORZ-9 were found to be slightly irregular while others, ORZ-1, ORZ-2 and 
ORZ-3 were found to be very irregular in shape. The regression equation of particle size 
for MUS was: 
Eq. 2.   Y1 = 0.9983 + 0.1432 X1 + 0.1478X2  (r
2 = 0.886) 
The multiple regression data obtained for particle size indicated positive influence of the 
variables on the study, HPMC K4M exhibiting predominant effect than chitosan. The 
increasing viscosity of the solution caused by increasing both polymers concentration 
increases the droplet size and consequently the particle size. It also may be due to the fact 
that increased concentration of polymers, increases the crosslinking, and hence the matrix 
density of the MUS is also increased, which further results in the increase of the particle 
size of the MUS [13, 14]. The influence of the variables on the particle size of MUS was 
further elucidated using the response surface graph as shown in Fig. 1.The linear model 
generated for the geometric particle size was found to be significant with an F-value of 
23.33 (p<0.05).  
 
Fig. 1.   Response surface graph for the effect of variables on particle size. 
Drug entrapment efficiency 
The drug entrapment efficiency  was in the range of 80 ± 3.45% to 96 ± 3.27% 
(Table 1).The regression equation of encapsulation efficiency for MUS was: 
Eq. 3.   Y2 = 94.3333 − 8.1667 X1X1    (r
2 = 0.577)   Optimization, Characterisation and Pharmacokinetic Studies of Mucoadhesive Oral Multiple Unit …  185 
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Fig. 2.   Response surface graph for the effect of variables on entrapment efficiency. 
The negative result can be attributed to the concentration of chitosan on encapsulation 
efficiency. The decrease in entrapment efficiency with increase in chitosan concentration 
could be due to the increased binding of the main groups of the drug to the added chitosan 
[15]. The influence of the variables on the entrapment efficiency of the MUS was further 
elucidated using the response surface graph (Fig. 2).The linear model generated for the 
entrapment efficiency was found to be significant with an F-value of 9.57 (p<0.05). All the 
formulations showed high entrapment efficiency irrespective of the polymer concentration. 
(A)  (B) 
Fig. 3.  Swelling ratio of ornidazole MUS in (A) 0.1 N HCl pH 1.2 (B) Phosphate buffer 
pH 6.8 
Swelling studies 
Swelling of MUS was influenced by the environmental pH. The swelling ratio of MUS in 
0.1N HCl ranged between 16.70 ± 0.29 to 29.01 ± 0.19 (Fig. 3A). The MUS of ORZ-5 and 
ORZ-6 batches displayed the highest swelling in 0.1N HCl, which might be due to high 
concentration of HPMC K4M which swells rapidly in acidic medium. The swelling in 186  G. S. Asane et al.:  
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phosphate buffer (Fig. 3B) ranged between 16.82 ± 4.57 to 33 ± 8.86. Increase in HPMC 
K4M and chitosan concentration resulted in slightly decreased swelling behaviour in 
phosphate buffer. This may be due to insolubility of chitosan in alkaline conditions. The 
properties of the polymers were generally affected by their swelling behaviour, water 
uptake and hydration state [16].Therefore, a slow swelling is a requisite to avoid the 
formation of an over hydrated form that loses its integrity before the drug release at the 
target. The intact nature of the MUS is required to maintain a slow drug release during 
their transit through GIT. The batches ORZ-6, ORZ-7 and ORZ-9 were found to remain 
intact, whereas ORZ-3, ORZ-5 changed their shape and remaining batches were totally 
disintegrated. 
Mucoadhesion testing by in vitro wash-off method 
MUS consisting of alginate, HPMC K4M and chitosan in different concentrations exhibited 
good mucoadhesive properties in the in vitro wash-off test as shown in Fig. 4. The wash-
off was faster at intestinal pH (33 ± 1.00 to 90.33 ± 1.52) than at gastric pH (60 ± 2.00 to 
90 ± 1.00). The rapid wash-off was observed at intestinal pH 6.8, a pH at which ionization 
of carboxyl and other functional groups of the polymer occurs leading to increase in their 
solubility and reduction of adhesive strength [17]. The adhesion number was found to be 
increased with increase in amount of both the polymers because more amount of polymer 
results in higher amount of free –NH2 groups, which are responsible for binding with sialic 
acid groups in mucus membrane and thus results in increase in mucoadhesive properties 
[18]. The initial inter-action between the polymer and the biological surface is through 
electrostatic interaction followed by mechanical interlocking of the polymer chains. 
Therefore, the surface charge density of polymers is important for electro-static behavior 
during the adhesion process [16].The results of the wash-off test indicated that the MUS 
demonstrated fairly good mucoadhesive properties under acidic conditions. 
 
Fig. 4.   Mucoadhesion testing of different ornidazole formulations in pH 1.2 and pH 6.8 
at 12 h (n=3).   Optimization, Characterisation and Pharmacokinetic Studies of Mucoadhesive Oral Multiple Unit …  187 
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Drug release study  
The drug release analysis was performed by taking data of phosphate buffer pH 6.8 and 
complete dissolution of drug from the MUS occurred within 13h as shown in Fig. 5A. The 
drug release was initially rapid followed by steady state.The ideal drug release up to 12 h 
was shown by ORZ-6, ORZ-7, and ORZ-8.The regression equation for time taken to 
release the drug in phosphate medium was as follows: 
Eq. 4.  Y 3 = 8.0070 − 1.3273 Χ1   (r
2=0.886) 
Tab. 2.   Model fitting of in-vitro release data using correlation coefficient (r
2) and n 
values. 
Zero order  First order Matrix Hixson–Crowell Peppas  Formul. 
r
2 
n 
ORZ-1 0.882  0.993  0.964 0.972  0.963  0.834
ORZ-2 0.712  0.964  0.955 0.915  0.933  0.615
ORZ-3 0.574  0.937  0.947 0.863  0.935  0.484
ORZ-4 0.763  0.949  0.968 0.915  0.967  0.562
ORZ-5 0.679  0.933  0.955 0.875  0.912  0.598
ORZ-6 0.831  0.965  0.964 0.943  0.954  0.743
ORZ-7 0.893  0.982  0.964 0.965  0.972  0.834
ORZ-8 0.888  0.964  0.957 0.944  0.958  0.953
ORZ-9 0.892  0.982  0.968 0.963  0.962  0.875
 
The multiple regression equation revealed retarding effect of chitosan on drug release, 
which might have caused by slower penetration of medium in highly cross-linked MUS due 
to formation of a three dimensional gel structure leading to immobilization of water 
molecules inside it and slowing drug release in buffer [19]. When the amount of polymer is 
increased the crosslink density increases which causes barrier for drug diffusion and 
hence the rate of release decreases and t80% increases. The influence of the variables on 
the t80% of drug release was further elucidated using the response surface graph 
(Fig. 5B).The linear model generated for the geometric percent drug release was found to 
be significant with an F-value of 6.61 (p < 0.05). The figure reveals that drug release rate 
was slowed after 4 h. The batch ORZ-6 exhibited a high t80% of 530 min and seems to be a 
promising candidate for achieving drug release up to 10 h. The model fitting of the in vitro 
release profile (Table 2) in different release kinetics models and comparison of the 
coefficient of determination (r
2) showed that release data of ORZ-1, ORZ-2 and ORZ-6 to 
ORZ-9 obeys first order kinetic; whereas of ORZ-3 to ORZ-5 follows matrix model kinetics. 
To justify the results, power law was applied and from the diffusion coefficient value (n), it 
was found that ORZ-1, ORZ-2 and ORZ-4 to ORZ-9 formulations follow anomalous 
diffusion transport mechanism while ORZ-3 follows Fickian diffusion. This can be attributed 
to the fact that the drug release from the MUS did not follow uniform geometry; instead the 
drug got released through fractal rearrangements of polymeric chain. An ideal drug release 
up to 12 h was shown by ORZ-4, ORZ-5 and ORZ-6. The percent of the drug released for 
ORZ-6 at the end of 5,10 and 12 hours was 68,87 and 93%,respectively.The drug release 
was highly extended from ORZ-7, ORZ-8 and ORZ-9 which contain higher concentration 
of HPMC K4M that forms a swollen gel with greater structural integrity and greater 
entanglement holding excess of medium.  188  G. S. Asane et al.:  
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(A)  (B) 
Fig. 5.   (A) In-vitro release profile of ORZ MUS in phosphate buffer pH 6.8.  
(B) Response surface graph for the effect of variables on t80% of drug release. 
Gastrointestinal Transit (GI) behaviour 
As compared to the normal gastric residence time of the conventional formulations from 5 
minutes to 2 hours, the residence time of ORZ-6 MUS was found to be improved. The 
fluoroscopic study revealed that the MUS remained in the stomach for 30–60 minutes and 
then passed into the upper intestinal tract where they stayed up to 3 h, followed by the 
small intestine up to 6 h and retained for longer time in the colon for more than 6 h. The 
administered formulation could not be detected after 24 h possibly due to the degradation 
of polymers in the colon and/or evacuation during the passage of the bowel. X-ray 
photographs obtained at 5 h showed maximum number of MUS in the small intestine when 
compared to transit time of small intestine of 3–4 h, as most of the drugs are absorbed 
through it due to its huge surface area [20] as shown in Fig. 6. The tested formulation 
could be useful for the sustained delivery of ornidazole as it stayed at different sites and 
spread over a larger area of the GIT. There was no significant effect of food in the transit 
of the MUS with mucoadhesive polymers. 
 
(A) (B)  (C) 
Fig. 6.   X-ray photographs recorded at (A) 0.5 h, (B) 2 h and (C) 5 h after oral 
administration of blank formulation of ORZ-6 in human volunteers.   Optimization, Characterisation and Pharmacokinetic Studies of Mucoadhesive Oral Multiple Unit …  189 
Sci Pharm. 2011; 79: 181–196 
In vivo bioavailability study 
The ORZ-6 formulation was selected for bioavailability studies due to its good swelling 
property in acidic and alkaline conditions and also possessing good bioadhesive property 
in both the media, while Ornida
® IR 500 mg tablet was selected because no sustained 
release formulation of ornidazole was available in Indian market. The values of 
pharmacokinetic parameters were tested for equality of variance; on acceptance of the 
hypothesis, paired t-test was used to test the significance of the observed difference in 
pharmacokinetic parameters; else, the t-test with unequal variance was used to test the 
significance. The mean plasma concentrations of ornidazole at each time point following 
administration of ORZ-6 and Ornida
® are shown in Fig.  7 and the pharmacokinetic 
parameters are listed in Table 3.  
 
Fig. 7.   Mean serum levels of ornidazole after oral administration of formulation ORZ-6 
and Ornida
® 500 mg tablets. Each point represents mean value ± standard 
deviation (n =8). 
The peak concentration (Cmax) of Ornida
® tablet and ORZ-6 MUS was 14.48 ± 1.27 and 
9.03 ± 0.73µg/ml, respectively with a significant difference of (P<0.0001) with each other. 
The time to reach peak concentration (Tmax) of Ornida
® tablet and ORZ-6 MUS was 3.00 ± 
0.16 and 8.00 ± 0.22 h, respectively with significant difference of (P<0.0001) with each 
other. The extent of absorption is a key factor of the formulation and therefore the 
absorption rate constant (ka) and AUC are important parameters for analysis in a 
comparative bioavailability study. Ornidazole was found absorbed at a faster rate resulting 
in a sudden spike of the drug level in plasma after oral administration of IR tablet. Though 
there was a delay in the appearance of the drug after the oral administration ORZ-6 MUS, 
similar spike in the drug levels was observed after 3 h. The absorption rate constant of 
ORZ-6 was 0.73±0.004 (1/h) when compared to Ornida
® with 5.32 ± 1.48 (1/h) with a 
significant difference of (P<0.0001) with each other. The mean elimination half-life for 
ornidazole following oral ingestion of IR tablet and ORZ-6 MUS were 5.36 ± 0.45 and 6.83 
± 1.15 h, respectively which were not significantly different. After administration of Ornida
® 
tablet and ORZ-6 MUS, AUC0–24 attained was 114.49 ± 12.88 and 170.68 ± 11.93 µg-h/ml, 
while, the AUCtotal was 120.78 ± 24.32 and 200.71 ± 45.92µg.h/ml, respectively 190  G. S. Asane et al.:  
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(P<0.0033). The MRT of Ornida
® tablet and ORZ-6 MUS was 10.46 ± 1.20 h and 20.13 ± 
2.83 h, respectively (P<0.0063). The Cmax, Tmax and AUC0-t obtained with ORZ-6 MUS and 
Ornida
® tablet when compared with paired t -test showed significant difference (P<0.05) 
between the two formulations. This difference may be due to the reason that one product 
is administered as immediate release tablet and other as gastro retentive sustained 
release formulation. Thus, the bioavailability was improved as compared to immediate 
release marketed product. This also establishes the fact that the developed ORZ-6 
formulation was effective and better than the marketed tablet dosage form. Higher 
bioavailability with same dose and showing sustained effect can be considered as better 
qualities of the developed formulations. 
Tab. 3.   Pharmacokinetics of ornidazole following oral administration of formulation 
ORZ-6 and Ornida
® 500 mg tablets (n=8). 
Ornida
® ORZ-6 Significance  Pharmacokinetic parameters 
Mean (±SD)  Mean (±SD)  Difference (p<0.05)
Cmax (µg/ml)  14.48 ± 1.27  9.03 ± 0.73  P<0.0001 
Tmax (h)  3.00 ± 0.16  8.00 ± 0.22  P<0.0001 
AUC0–24 (µg.h/ml)  114.49 ± 12.88 170.68 ± 11.93 P<0.0033 
AUCTotal (µg.h/ml)  120.78 ± 24.32 200.71 ± 45.92 P<0.0033 
mean residence time (h)  10.46 ± 1.20  20.13 ± 2.83  P<0.0063 
Terminal half-life, t1/2 (h)  5.36 ± 0.45  6.33 ± 1.15  P<0.05 
Absorption time, ta (h)  0.91 ± 0.05  5.83 ± 0.001  P<0.0001 
Absorption rate constant, ka (1/h)  5.32 ± 1.48  0.73 ± 0.004  P<0.0001 
SD indicates standard deviation 
 
Experimental 
Materials 
Model drug ornidazole and metronidazole (internal standard) were gift samples from J. B. 
Chemicals Ltd, Ankleshwar, India. Chitosan (degree of deacetylation of 85%) was gifted by 
Central institute of fisheries technology, Kochi, India. Hydroxypropyl methylcellulose K4M 
(HPMC K4M, having a viscosity of 50 cps in a 2% w/v aqueous solution at 20°C) was 
kindly supplied by Colorcon Asia Pvt. Ltd. Sodium alginate (SK Fine Chem, Mumbai, India) 
and calcium chloride (Qualigens, Mumbai, India) were procured from commercial sources. 
Marketed ornidazole 500mg tablets (Ornida
® IR) used as reference product for 
bioavailability studies were purchased from local market (Loni, India). All other reagents 
and solvents used were of analytical grade procured from Merck, Mumbai, India. 
Methods 
Preparation of MUS by ionic gelation method [21] 
Sodium alginate (2%w/v), HPMC K4M and chitosan in varying composition (Table 1) were 
dissolved in purified water 100ml to form a homogeneous polymer solution. The active 
substance ornidazole (2.0 g) was added to the polymer solution and mixed thoroughly with 
a stirrer to form a viscous dispersion. The resulting dispersion was then added manually   Optimization, Characterisation and Pharmacokinetic Studies of Mucoadhesive Oral Multiple Unit …  191 
Sci Pharm. 2011; 79: 181–196 
dropwise into slowly agitated 100ml calcium chloride solution (2.5%w/v) through a syringe 
having a needle of size 16G. The added droplets were retained in the calcium chloride 
solution for 15 minutes to complete the curing reaction and to produce spherical rigid 
MUS. The MUS were collected by decantation and the product thus separated was 
washed repeatedly with 2x100ml volumes of de-ionized water and dried at room 
temperature for 12 h.  
Optimization by Factorial design experiments 
A full 3
2 factorial design was constructed and conducted to optimise the levels of the 
independent variables chitosan (X1) and HPMC K4M (X2).The dependent variables 
selected for the study were particle size (Y1), drug entrapment efficiency (Y2) and time 
taken for 80% of drug release (t80%) (Y3). The coded and actual value of variables for each 
batch and the experimental design are given in Table 1. The range of a factor was chosen 
in order to adequately measure its effect on the response variables.  
Determination of Particle Size 
Twenty five MUS from each batch were subjected to determination of particle size by 
digital micrometer (Mitutoyo, Japan). Using the frequency data, the log normal distribution 
on a probability scale was plotted and the geometric mean diameter and the geometric 
standard deviation were calculated. 
Drug entrapment efficiency 
Drug loaded MUS (50 mg) were placed in 250 ml conical flask containing 100 ml of 0.1N 
HCl solution in water. The MUS were stirred to release ornidazole completely. These 
solutions were centrifuged and filtered through a 0.45 µm membrane filter. The filtrate was 
then sufficiently diluted with 0.1N HCl solution. Aliquots of these solutions were subjected 
in triplicate to ultraviolet spectroscopy at 254 nm against 0.1N HCl solution as blank. 
Eq. 5.   100  
content   drug   percentage   l Theoretica
content   drug   percentage   Estimated
    efficiency   sulation Microencap × =  
Swelling studies 
Known quantities of MUS (100 mg) of different batches were placed in 10 ml volumetric 
graduated measuring cylinders containing 0.1 N HCl pH 1.2 for 4 h and phosphate buffer 
pH 6.8 for 8 h. The length of MUS in graduated measuring cylinder was measured at 
appropriate time intervals. The studies were performed in triplicate and average volume of 
MUS was calculated. The relative swelling of MUS was calculated as percentage of the 
volume at time 0. 
Mucoadhesion testing by in vitro wash-off method 
The mucoadhesive property of MUS was evaluated by an in vitro adhesion testing method 
known as the wash-off method as reported by Lehr et al [22]. The mucoadhesive property 
of the MUS was compared within the batches. The freshly excised pieces of intestinal 
mucosa of sheep was obtained from slaughter house and stored in Tyrode solution. The 
pieces (2×2 cm) were mounted onto glass slides (3×1 inch) with cyanoacrylate glue. Two 
glass slides were connected with a suitable support. About 25 (n=3) MUS were spread on 192  G. S. Asane et al.:  
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to each wet rinsed tissue specimen and immediately thereafter the support was hung on to 
the arm of a USP tablet disintegrating test machine. When the disintegrating test machine 
was operated, the tissue specimen was given a slow, regular up and down movement in 
the test fluid at 37° ± 0.5°C contained in a 1 litre vessel of the machine. At the end of 30 
min, at the end of 1 h and at hourly intervals up to 12 h the machine was stopped and the 
number of MUS still adhering to the tissue was counted. The test was performed at both 
gastric pH 1.2 and intestinal pH 6.8. It is assumed that as the adhesion strength increases, 
the adhesion number also increases. The adhesion number (Na) is defined as the ratio 
between the number of particles (N) remaining after the application of a certain 
detachment force and the number of particles (No) originally present on the test surface. 
The adhesion number is often expressed as a percentage.  
Eq. 6.   100
0
× =
N
N
Na  
Drug release study  
In vitro drug release from MUS was studied by means of a USP type II dissolution test 
apparatus (EDT-06 L, Electrolab, India) in phosphate buffer pH 6.8 for 13h at the speed of 
100 rpm at 37±0.5
°C. Samples of dissolution fluid were withdrawn through a cellulose 
nitrate filter (0.45μm) at different time intervals and were assayed spectrophotometrically 
at 319nm using a Shimadzu UV-150 double-beam spectrophotometer (Shimadzu 
Corporation, Japan). The drug release experiments were conducted in triplicate (n = 3). 
Analysis and model fitting [23] of data was done by using “PCP Disso V3” software (IIPC, 
PCP, Pune, India). 
Gastrointestinal Transit (GI) Behaviour 
The GI transit behaviour of the formulation was visualized using fluoroscopy (low energy 
X-rays, Siemens Fluorovision, Germany) under the supervision of a radiologist. The study 
protocol was approved by the Institutional Ethical Committee (Kakatiya University, 
Warangal, India, and No-UCPSC/BA/2009-05). Three healthy human male volunteers of 
age and weight ranging from 23 to 29 years and 62 to 70 kg were selected for the study. A 
written consent was obtained from them. The MUS containing radio-opaque marker 
(barium sulphate) were prepared in a similar manner to formulation ORZ-6 by replacing 
the drug. The gelatin capsules containing 50 MUS each were administered to each subject 
with 200 ml of water after the subjects had fasted overnight. Lunch was provided 5 h after 
administration of radio-opaque formulation. During the experiments the subjects remained 
in a sitting or upright posture. All X-ray films were taken in anterior positions. 
In vivo bioavailability study 
The bioavailability protocol was approved by the Institutional Ethical Committee (Kakatiya 
University, Warangal, India). Eight healthy male volunteers in the age group of 25–30 
years (60–65 kg) participated in the study and all were non-alcoholics and non-smokers. 
The required biochemical tests were carried out to ensure that the volunteers were free 
from either liver or kidney dysfunction. None of the volunteers was on drug treatment 10 
days prior to participation in the study. The nature and purpose of the study were fully 
explained to them. An informed written consent was obtained from every volunteer. They   Optimization, Characterisation and Pharmacokinetic Studies of Mucoadhesive Oral Multiple Unit …  193 
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were allowed to withdraw from the study at any time, if they desire so. A crossover single 
dose study was followed. The volunteers were divided into two equal groups (group I and 
group II). Group I volunteers (n=8) received Ornida
® immediate release tablets (Batch 
no.175A019,Aristo Pharmaceuticals ltd, India) (dose 500 mg) whereas group II (n=8) 
volunteers received developed formulation ORZ-6 (dose 500 mg).The required amount of 
formulation ORZ-6 was dispensed into hard gelatin capsules. A light breakfast was 
provided after overnight fasting. After 30 minutes capsules and Ornida
® IR 500 mg tablets 
were administered to each subject with 200 ml of water. Lunch was provided 4 h after drug 
administration. Blood samples of 5 ml were collected at 0, 0.5, 1, 1.5, 2, 3, 5, 8, 10, 12, 24 
and 34 h. The samples were allowed to clot and centrifuged at 3000 rpm for 10 minutes. 
Serum was separated and stored at −20°C until analysis.  
Estimation of Ornidazole in human serum 
Analysis of ornidazole in human plasma samples was done by HPLC method reported by 
Y.S.R. Krishnaiah et al with slight modification [24]. The standard stock solution of 
ornidazole and metronidazole (internal standard) were prepared by dissolving 10 mg of 
each drug in 100 ml of double distilled water in separate volumetric flasks to get 
concentration of 100µg/ml. The stock solution of ornidazole was further diluted with double 
distilled water to get series of working standard solutions having concentration 0.6, 1.2, 3, 
6, 12, 18, 24 and 30µg/ml. 12 ml of metronidazole stock solution was further diluted to 20 
ml with double distilled water to get standard solution of concentration 60 µg/ml. 1 ml of 
each working standard solution of ornidazole (0.01–25 µg/ml) was transferred in a series 
of eppendorf tubes (Eppendorf-Netheler-Hinz, Hamburg, Germany) containing 1ml of 
human plasma separately. In each flask 0.5 ml solution of metronidazole (60 µg/ml) and 
3.5 ml of acetonitrile was added for complete precipitation of proteins. The tubes were 
vortexed for 10 minutes on vortex mixer and then centrifuged for 10 min at 3500 rpm. The 
HPLC system was equipped with a pump (LC-10AT, Shimadzu, Japan), an injection port 
(Rheodyne, USA), a reversed phase C18 column (250 4.6 mm, 5 m, Phenomenex, USA) 
and a UV detector (SPD 10A, Shimadzu, Japan). HPLC mobile phase was composed of 
10 mM KH2PO4 (pH 4.7): Acetonitrile (80: 20, v/v) at a flow rate of 1 ml/min with the 
detector wavelength set at 254 nm. The retention times of metronidazole and ornidazole 
were 5.48 and 9.15 minutes respectively. The peak area ratios of ornidazole to 
metronidazole were calculated and plotted against the respective concentrations of 
ornidazole to obtain the calibration curve. A good linear relationship was observed 
between the concentration of ornidazole and the peak area ratio of ornidazole to that of 
internal standard with a high correlation coefficient (r=0.999) in the range of 0.01–25 
µg/ml. The method was found to be precise (intra- and inter- day variation was found to be 
less than 2%) and accurate (mean recovery 99.8%). 
Pharmacokinetics of MUS [25]  
Peak plasma concentration (Cmax), the corresponding times at which these are reached 
(Tmax), the area under the serum concentration time curve (AUC) and Mean Residence 
Time (MRT) for individual subjects were calculated using KINETICA
TM software (Inna 
Phase Corp., 2000). All the data was statistically analyzed using Sigmastat software 
package (Jandel Corp., California). Half-life (t1/2): The overall elimination rate constant (ke) 
was calculated from the slope of the terminal elimination phase of a semi-logarithmic plot 
of concentration versus time, after subjecting it to linear regression analysis. Assuming the 
elimination to be a first-order process: t1/2 =0.693/ke, where ke = −slope × 2.303, while 194  G. S. Asane et al.:  
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absorption rate constant  (ka) was obtained by assuming first-order kinetics using the 
equation: ka=4.61/ta, where ta is the absorption time obtained from a semi-logarithmic plot 
of concentration versus time data [26]. Paired t-test was used for comparison of 
pharmacokinetic parameters and the difference was considered significant when p<0.05. 
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